drugset / Trial / NCT00159731
Safety of Pregabalin in the Treatment of Pain Due to Diabetic Peripheral Neuropathy
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to 1) provide continued pregabalin treatment for 6 additional months to patients who have taken part in the placebo controlled study A0081060; and 2) find out if pregabalin is safe at a dose of 600 mg/day (taken twice a day)
Timeline
- Start
- 2005-01
- Primary completion
- —
- Completion
- 2006-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pregabalin | Small molecule | 600 mg | — |